ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,323.00
-0.04%
S&P ASX All Technology
3,880.20
0.04%
Brent Oil
73.485
0.89%
US Dollar vs AUD
1.53454
-0.07%
Bitcoin
98,110.16
3.98%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. AMEX

  6. Palatin Technologies Inc New (PTN) Share Price

Palatin Technologies Inc New

Palatin Technologies Inc New (PTN)

Patronus Resources Ltd
Palatin Technologies Inc
Proton Capital Corp
0.9214
0.0072
( 0.79% )
Updated: 04:53:29
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
0.9214
Bid
-
Offer
-
Volume
60,766
0.9142 Day's Range 0.9669
0.68 52 Week Range 5.65
Market Cap
18.012M
Previous Close
0.9142
Open
0.92
Last Trade
25
@
0.9499
Last Trade Time
04:54:52
Financial Volume
US$ 57,043
VWAP
0.938725
Average Volume (3m)
285,123
Shares Outstanding
19,548,167
Dividend Yield
-
PE Ratio
-0.60
Earnings Per Share (EPS)
-1.52
Revenue
4.49M
Net Profit
-29.74M

About Palatin Technologies Inc New

Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the me... Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
palatin.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Palatin Technologies Inc New is listed in the Pharmaceutical Preparations sector of the American Stock Exchange with ticker PTN. The last closing price for Palatin Technologies was US$0.91. Over the last year, Palatin Technologies shares have traded in a share price range of US$ 0.68 to US$ 5.65.

Palatin Technologies currently has 19,548,167 shares in issue. The market capitalisation of Palatin Technologies is US$17.87 million. Palatin Technologies has a price to earnings ratio (PE ratio) of -0.60.

Ask ADVFN Intelligence (AI)

PTN Latest News

More News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

15 November 2024
Edgar (US Regulatory)

Form 8-K - Current report

15 November 2024
Edgar (US Regulatory)

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results PR Newswire CRANBURY, N.J., Nov. 14, 2024 Obesity programs:Core focus on obesity includes exploratory co-administration...

14 November 2024
PR Newswire (US)

Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024

Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024 PR Newswire CRANBURY, N.J., Nov. 8, 2024 CRANBURY, N.J., Nov. 8, 2024...

09 November 2024
PR Newswire (US)

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024 PR Newswire CRANBURY, N.J., Nov. 4, 2024 Oral PL7737 significantly...

04 November 2024
PR Newswire (US)

Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity

Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity PR Newswire CRANBURY, N.J., Oct...

31 October 2024
PR Newswire (US)

Form 424B3 - Prospectus [Rule 424(b)(3)]

31 October 2024
Edgar (US Regulatory)

Form EFFECT - Notice of Effectiveness

30 October 2024
Edgar (US Regulatory)

Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium

Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium PR Newswire CRANBURY, N.J., Oct. 24, 2024 Data...

24 October 2024
PR Newswire (US)

Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium

Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium PR Newswire CRANBURY, N.J., Oct. 23, 2024 High...

23 October 2024
PR Newswire (US)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.1786-16.23636363641.11.10.92306160.970768CS
4-0.1786-16.23636363641.11.40.92666951.14950347CS
12-0.7186-43.81707317071.641.720.682851231.06312516CS
26-1.1486-55.48792270532.072.130.681948521.25767676CS
52-0.9686-51.24867724871.895.650.683398772.28521439CS
1560.5464145.7066666670.3758.60.181110690980.8529184CS
2600.130816.54439666080.79068.60.181115731670.75479002CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BIGYYieldmax Target 12 Big 50 Option Income ETF
 49.955
(176.15%)
13.89k
SNOYYieldmax Snow Option Income Strategy ETF
US$ 22.245
(26.68%)
49.13k
HYLNHyliion Holdings Corp
US$ 3.5799
(23.02%)
2.63M
MGLDMarygold Companies Inc
US$ 1.45
(20.83%)
15.19k
ETUT Rex 2X Long Ether Daily Target ETF
US$ 41.87
(18.54%)
44.53k
CATXPerspective Therapeutics Inc
US$ 3.36
(-45.54%)
7.44M
ETQT Rex 2X Inverse Ether Daily Target ETF
US$ 11.54
(-18.24%)
6.16k
ETHDProshares Ultrashort Ether ETF
US$ 25.90
(-17.62%)
103.55k
ROLRHigh Roller Technologies Inc
US$ 6.0902
(-16.00%)
18.9k
EFSH1847 Holdings LLC
US$ 0.3428
(-13.11%)
2.28M
MSTZT Rex 2X Inverse MSTR Daily Target ETF
US$ 0.846601
(4.16%)
994.35M
SOXLDirexion Daily Semiconductor Bull 3X Shares
US$ 28.29
(4.28%)
66.74M
NVDQT Rex 2X Inverse NVIDIA Daily Target ETF
US$ 3.1387
(2.57%)
55.19M
SPXSDirexion Daily S&P 500 Bear 3X Shares New
US$ 6.0898
(-1.46%)
52.48M
ETHU2x Ether ETF
US$ 8.685
(17.52%)
29.04M

PTN Discussion

View Posts
zeusgodmd zeusgodmd 1 day ago
Meibo eye drops just came out for dry eyes saw commercial 
👍️0
zeusgodmd zeusgodmd 1 month ago
Far off from 17$ though
👍️0
zeusgodmd zeusgodmd 1 month ago
Looking good
👍️0
zeusgodmd zeusgodmd 1 month ago
Let hear about a partnership
👍️0
zeusgodmd zeusgodmd 1 month ago
Let’s go Merck or Pfizer
👍️0
zeusgodmd zeusgodmd 1 month ago
Got mine
👍️0
zeusgodmd zeusgodmd 2 months ago
Loaded thanks for the share price let’s see what happens in the next 6 months
👍️0
zeusgodmd zeusgodmd 2 months ago
Last of the cheapies
👍️0
zeusgodmd zeusgodmd 2 months ago
Wainwright really confident the stock going to see 17$ can’t wait
👍️0
zeusgodmd zeusgodmd 2 months ago
Bottom shot until partners get established
👍️0
zeusgodmd zeusgodmd 2 months ago
I guess it’s the atm for the company or eye drug not approved will see on the first
👍️0
zeusgodmd zeusgodmd 2 months ago
I bought this many shares yesterday
👍️0
zeusgodmd zeusgodmd 2 months ago
Maybe some seller didn’t put a limit on his sell. He won’t do that again
👍️0
zeusgodmd zeusgodmd 2 months ago
Not as easy to get today
👍️0
zeusgodmd zeusgodmd 2 months ago
Cat must be out of the bag
👍️0
Monksdream Monksdream 3 months ago
PTN under $2
👍️0
zeusgodmd zeusgodmd 3 months ago
I got enough for the ride
👍️0
zeusgodmd zeusgodmd 3 months ago
Time to load up
👍️0
Monksdream Monksdream 4 months ago
PTN under $2
👍️0
Monksdream Monksdream 5 months ago
PTN under $2
👍️0
mike1986 mike1986 7 months ago
You may just get your wish. This stock has been making promises for years and now expects everyone to wait until 2025 for any hope of marketing its dry eye ointment, while looking for a partner to do the heavy lifting. Ahhhhhhh..........
👍️0
Stockexpertpro Stockexpertpro 7 months ago
PTN Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024

https://finance.yahoo.com/news/palatin-announces-phase-3-pl9643-113000533.html
👍️0
zeusgodmd zeusgodmd 8 months ago
Waiting for 1.25
👍️0
Monksdream Monksdream 8 months ago
PTN under $2
👍️0
mte1955 mte1955 9 months ago
Well just great. Pump it the few days before the announcement and sell it on the news.
👍️0
mike1986 mike1986 9 months ago
I love the way these low cap stocks move up and down on no news.
👍️0
mike1986 mike1986 9 months ago
On the move with high volume. Hope something announced soon.
👍️ 1
mte1955 mte1955 9 months ago
So I guess people are disappointed with the latest report. Nothing new but nothing detrimental either.
👍️0
zeusgodmd zeusgodmd 10 months ago
Did not see that coming. Why can’t they what. Til after the news
👍️0
zeusgodmd zeusgodmd 10 months ago
Guess no news this week
👍️0
zeusgodmd zeusgodmd 11 months ago
There are people here that seem to start buying 3 days before a big announcement but everybody is looking at before the end of the year will see
👍️0
power11 power11 11 months ago
ANY SPECIFIC DATE ???
THANKS
👍️0
zeusgodmd zeusgodmd 11 months ago
News next week
👍️0
zeusgodmd zeusgodmd 1 year ago
Good luck in am. Need a new partner to launch eye sauce. Royalty payments with a down payment. New sex med, new Ibs med why are we at 2$
👍️0
zeusgodmd zeusgodmd 1 year ago
It was going a nice direction why fk it up.
👍️0
mike1986 mike1986 1 year ago
Seems more like unloading today. Buy the rumor, sell the news.
👍️0
zeusgodmd zeusgodmd 1 year ago
Highest volume in over a year will take it. Money managers starting the load
👍️0
zeusgodmd zeusgodmd 1 year ago
Stepping up the right way
👍️0
zeusgodmd zeusgodmd 1 year ago
It’s only up one buck a lot more money to be made
👍️0
johnb214 johnb214 1 year ago
All time is around 1,670.00. A large Pharma should buy the stock and acquire it versus just paying for one or two of their drugs.
👍️0
zeusgodmd zeusgodmd 1 year ago
Nice moves not 8 yet
👍️0
zeusgodmd zeusgodmd 1 year ago
Last 3 days tells the story people loading the boat
👍️0
zeusgodmd zeusgodmd 1 year ago
Hw investors calling for 75$ I’ve seen that call once by them at it was right on rambus stock
👍️0
zeusgodmd zeusgodmd 1 year ago
Not to 8$ yet
👍️0
zeusgodmd zeusgodmd 1 year ago
Will take shorts 5 days to cover. Good run
👍️0
zeusgodmd zeusgodmd 1 year ago
Stock going to get out of the shitter soon should be 8$
👍️0
zeusgodmd zeusgodmd 1 year ago
They need to start looking for a marketing and sale partnership for eye product and Ibs product
👍️0
zeusgodmd zeusgodmd 1 year ago
Good loading day. Good news will come.
👍️0
zeusgodmd zeusgodmd 1 year ago
Maybe falls to floor tomorrow time to buy good luck to sll
👍️0
zeusgodmd zeusgodmd 1 year ago
It time for them to get in bed with a eye company and get some funding and royalty plans with them.
👍️ 1

Your Recent History

AMEX
PTN
Palatin Technologies
ASX
PRU
Perseus Mining
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved